![SaI [Sa I, Sarcoma I]](http://www.family998.com/static/images/cells-no_picture.jpg)
-
平臺編號：bio-68778
-
國際編號：CRL-2543?
-
細(xì)胞信息： SaI [Sa I, Sarcoma I]
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費用：
加載中…… - 訂購
-
注意事項：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
SaI [Sa I, Sarcoma I]
生長狀態(tài)：懸浮生長
數(shù)量：大量
運(yùn)輸方式：凍存運(yùn)輸
ATCC Number：CRL-2543?
相關(guān)疾?。浩渌膊?br /> 細(xì)胞形態(tài)：淋巴樣
細(xì)胞類型：其他細(xì)胞類型
是否是腫瘤細(xì)胞：0
物種來源：小鼠
規(guī)格：0.5ml Designations: SaI [Sa I, Sarcoma I]
Depositors: ?S Ostrand-Rosenberg
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus deposited as mouse
Morphology:lymphoblast
Source: Disease: fibrosarcoma, malignant
Cell Type: dibenzanthracene induced
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Antigen Expression:MHC class I +; MHC class II - [49807 ]
H-2a
Comments:The Sarcoma I tumor originated in 1947 in a mouse that had been treated with dibenzanthracene [53560 ]
The tumor grows progressively in the A/Jax subline of the Strong A mouse and kills 100% of the animals. In contrast, mice of the resistant C57BL/6K strain reject the tumor in about 100% of the cases. [53559 ]
The SaI variant (ATCC CRL-2543 ) grows as an ascites tumor when inoculated intraperitoneally, while the SaI/N variant grows as a solid tumor when inoculated subcutaneously [49807 ]
The cell line can be used as a model for testing immunotherapy protocols. It can be used in immunology and cancer studies. The cells may be used for transfection studies.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 X 10(5) viable cells/ml.
Interval: Maintain cell density between 5 X 10(5) and 2 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
References: 49807: Baskar S, et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619-629, 1995. PubMed: 7836917
53559: Baker P, et al. Mechanisms of tumor homograft rejection: The behavior of Sarcoma I ascites tumor in the A/Jax and the C57BL/6K mouse. Ann. N.Y. Acad. Sci. 101: 46-63, 1962.
53560: Dunham LJ, Stewart HL. A survey of transplantable and transmissible animal tumors. J. Natl. Cancer Inst. 13: 1299-1377, 1953. PubMed: 13035452
數(shù)量：大量
運(yùn)輸方式：凍存運(yùn)輸
ATCC Number：CRL-2543?
相關(guān)疾?。浩渌膊?br /> 細(xì)胞形態(tài)：淋巴樣
細(xì)胞類型：其他細(xì)胞類型
是否是腫瘤細(xì)胞：0
物種來源：小鼠
規(guī)格：0.5ml Designations: SaI [Sa I, Sarcoma I]
Depositors: ?S Ostrand-Rosenberg
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus deposited as mouse
Morphology:lymphoblast
Source: Disease: fibrosarcoma, malignant
Cell Type: dibenzanthracene induced
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Antigen Expression:MHC class I +; MHC class II - [49807 ]
H-2a
Comments:The Sarcoma I tumor originated in 1947 in a mouse that had been treated with dibenzanthracene [53560 ]
The tumor grows progressively in the A/Jax subline of the Strong A mouse and kills 100% of the animals. In contrast, mice of the resistant C57BL/6K strain reject the tumor in about 100% of the cases. [53559 ]
The SaI variant (ATCC CRL-2543 ) grows as an ascites tumor when inoculated intraperitoneally, while the SaI/N variant grows as a solid tumor when inoculated subcutaneously [49807 ]
The cell line can be used as a model for testing immunotherapy protocols. It can be used in immunology and cancer studies. The cells may be used for transfection studies.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 X 10(5) viable cells/ml.
Interval: Maintain cell density between 5 X 10(5) and 2 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
References: 49807: Baskar S, et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619-629, 1995. PubMed: 7836917
53559: Baker P, et al. Mechanisms of tumor homograft rejection: The behavior of Sarcoma I ascites tumor in the A/Jax and the C57BL/6K mouse. Ann. N.Y. Acad. Sci. 101: 46-63, 1962.
53560: Dunham LJ, Stewart HL. A survey of transplantable and transmissible animal tumors. J. Natl. Cancer Inst. 13: 1299-1377, 1953. PubMed: 13035452
